Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.

PubWeight™: 2.08‹?› | Rank: Top 2%

🔗 View Article (PMC 3338870)

Published in Nature on March 25, 2012

Authors

Aron M Levin1, Darren L Bates, Aaron M Ring, Carsten Krieg, Jack T Lin, Leon Su, Ignacio Moraga, Miro E Raeber, Gregory R Bowman, Paul Novick, Vijay S Pande, C Garrison Fathman, Onur Boyman, K Christopher Garcia

Author Affiliations

1: Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA.

Articles citing this

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity (2015) 1.57

Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med (2013) 1.53

Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest (2014) 1.45

Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol (2012) 1.41

Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites. Proc Natl Acad Sci U S A (2012) 1.34

Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nat Chem Biol (2012) 1.20

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov (2015) 1.14

Application of IL-2 therapy to target T regulatory cell function. Trends Immunol (2012) 1.11

Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol (2012) 1.10

Identification of a gene for an ancient cytokine, interleukin 15-like, in mammals; interleukins 2 and 15 co-evolved with this third family member, all sharing binding motifs for IL-15Rα. Immunogenetics (2013) 1.01

Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling. Proc Natl Acad Sci U S A (2013) 0.99

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Chem Biol (2014) 0.96

Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93

A designed conformational shift to control protein binding specificity. Angew Chem Int Ed Engl (2014) 0.93

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. Cancer Discov (2014) 0.93

T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93

NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer (2013) 0.91

Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett (2015) 0.91

The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res (2015) 0.91

In search of magic bullets: the golden age of immunotherapeutics. Cell (2014) 0.90

Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol (2014) 0.87

"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem (2015) 0.86

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol (2014) 0.84

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun (2016) 0.84

Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function. J Cell Biochem (2015) 0.83

Multifarious determinants of cytokine receptor signaling specificity. Adv Immunol (2014) 0.83

From systems to structure: bridging networks and mechanism. Mol Cell (2013) 0.83

Cytokines reinstate NK cell-mediated cancer immunosurveillance. J Clin Invest (2014) 0.82

Genetic variation in MHC proteins is associated with T cell receptor expression biases. Nat Genet (2016) 0.82

Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics. Front Immunol (2013) 0.81

Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity (2015) 0.81

T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med (2013) 0.81

Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection. Nat Immunol (2017) 0.80

Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection. Retrovirology (2015) 0.80

Structural basis of the proinflammatory signaling complex mediated by TSLP. Nat Struct Mol Biol (2014) 0.80

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One (2015) 0.79

Mechanistic model of natural killer cell proliferative response to IL-15 receptor stimulation. PLoS Comput Biol (2013) 0.78

Increasing affinity of interferon-γ receptor 1 to interferon-γ by computer-aided design. Biomed Res Int (2013) 0.78

Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice. Blood (2014) 0.78

Cytokine treatment in cancer immunotherapy. Oncotarget (2015) 0.78

IL-2/anti-IL-2 complex: a novel strategy of in vivo regulatory T cell expansion in renal injury. J Am Soc Nephrol (2013) 0.77

When the Scaffold Cannot Be Ignored: The Role of the Hydrophobic Core in Ligand Binding and Specificity. J Mol Biol (2015) 0.77

Role of IL-2 in cancer immunotherapy. Oncoimmunology (2016) 0.76

T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use Rictor/mTORC2 for proliferative checkpoint decisions. J Biol Chem (2016) 0.76

Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures. Nat Rev Immunol (2016) 0.76

Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76

Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes. J Biol Chem (2015) 0.75

Protein engineering: Tighter ties that bind. Nature (2012) 0.75

What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma? Immunotherapy (2012) 0.75

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology (2017) 0.75

Nuclear Phosphoproteomic Screen Uncovers ACLY as Mediator of IL-2-induced Proliferation of CD4+ T lymphocytes. Mol Cell Proteomics (2016) 0.75

IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy? Oncoimmunology (2015) 0.75

Quantitative Contribution of IL2Rγ to the Dynamic Formation of IL2-IL2R Complexes. PLoS One (2016) 0.75

IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep (2016) 0.75

Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis. Bioeng Transl Med (2017) 0.75

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure (2016) 0.75

Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun (2017) 0.75

Structural basis of GM-CSF and IL-2 sequestration by the viral decoy receptor GIF. Nat Commun (2016) 0.75

Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors. Oncoimmunology (2015) 0.75

Citizens unite for computational immunology! Trends Immunol (2015) 0.75

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. Oncoimmunology (2017) 0.75

Reprogramming cellular functions with engineered membrane proteins. Curr Opin Biotechnol (2017) 0.75

Roles for Innate Immunity in Combination Immunotherapies. Cancer Res (2017) 0.75

Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol (2017) 0.75

The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity. Immunity (2017) 0.75

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun (2017) 0.75

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One (2017) 0.75

Articles cited by this

Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01

Phaser crystallographic software. J Appl Crystallogr (2007) 108.34

PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61

Interleukin-2: inception, impact, and implications. Science (1988) 8.19

Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37

Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol (1997) 6.88

Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 6.38

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22

New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57

Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science (1989) 5.08

Isolating and engineering human antibodies using yeast surface display. Nat Protoc (2006) 5.02

Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature (1984) 4.95

Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05

Cloning, sequence and expression of human interleukin-2 receptor. Nature (1985) 3.02

Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science (2005) 2.64

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A (2010) 1.53

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A (2010) 1.50

Hot-spot mimicry of a cytokine receptor by a small molecule. Proc Natl Acad Sci U S A (2006) 1.47

Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol (2004) 1.01

The solution structure of the F42A mutant of human interleukin 2. J Mol Biol (1995) 0.95

Articles by these authors

FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 9.24

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78

STIM1 clusters and activates CRAC channels via direct binding of a cytosolic domain to Orai1. Cell (2009) 6.92

Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11

Absolute comparison of simulated and experimental protein-folding dynamics. Nature (2002) 5.68

Accelerating molecular dynamic simulation on graphics processing units. J Comput Chem (2009) 4.58

Automatic discovery of metastable states for the construction of Markov models of macromolecular conformational dynamics. J Chem Phys (2007) 4.52

DNA binding site sequence directs glucocorticoid receptor structure and activity. Science (2009) 4.48

Random-coil behavior and the dimensions of chemically unfolded proteins. Proc Natl Acad Sci U S A (2004) 4.44

Structural basis of Wnt recognition by Frizzled. Science (2012) 4.31

Exploring the helix-coil transition via all-atom equilibrium ensemble simulations. Biophys J (2005) 4.26

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04

In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med (2009) 3.78

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell (2008) 3.72

Homeostasis of memory T cells. Immunol Rev (2006) 3.69

Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (2013) 3.59

Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell (2009) 3.46

Multiplexed-replica exchange molecular dynamics method for protein folding simulation. Biophys J (2003) 3.35

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 3.25

How a single T cell receptor recognizes both self and foreign MHC. Cell (2007) 3.20

Molecular simulation of ab initio protein folding for a millisecond folder NTL9(1-39). J Am Chem Soc (2010) 3.18

The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol (2002) 3.09

Current status of the AMOEBA polarizable force field. J Phys Chem B (2010) 3.06

Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A (2006) 3.04

Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood (2004) 2.95

The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med (2002) 2.93

Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science (2003) 2.87

Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat Immunol (2007) 2.78

Heterogeneity even at the speed limit of folding: large-scale molecular dynamics study of a fast-folding variant of the villin headpiece. J Mol Biol (2007) 2.77

Solvation free energies of amino acid side chain analogs for common molecular mechanics water models. J Chem Phys (2005) 2.76

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76

Simulation of folding of a small alpha-helical protein in atomistic detail using worldwide-distributed computing. J Mol Biol (2002) 2.73

Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007) 2.70

Progress and challenges in the automated construction of Markov state models for full protein systems. J Chem Phys (2009) 2.64

Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science (2005) 2.64

Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol Cell (2003) 2.61

Using generalized ensemble simulations and Markov state models to identify conformational states. Methods (2009) 2.60

Molecular physiology of the WNK kinases. Annu Rev Physiol (2008) 2.58

Is it time for new initiatives in the blood center and/or the hospital to reduce bacterial risk of platelets? Transfusion (2011) 2.54

Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron (2007) 2.54

Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49

GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol (2007) 2.49

Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature (2002) 2.45

Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 2.39

An extracellular interactome of immunoglobulin and LRR proteins reveals receptor-ligand networks. Cell (2013) 2.36

Electric fields at the active site of an enzyme: direct comparison of experiment with theory. Science (2006) 2.32

Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science (2004) 2.32

Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. Science (2005) 2.32

Alchemical free energy methods for drug discovery: progress and challenges. Curr Opin Struct Biol (2011) 2.31

Comparison of efficiency and bias of free energies computed by exponential averaging, the Bennett acceptance ratio, and thermodynamic integration. J Chem Phys (2005) 2.31

Equilibrium free energies from nonequilibrium measurements using maximum-likelihood methods. Phys Rev Lett (2003) 2.30

Using path sampling to build better Markovian state models: predicting the folding rate and mechanism of a tryptophan zipper beta hairpin. J Chem Phys (2004) 2.30

Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A (2009) 2.30

Structural biology of shared cytokine receptors. Annu Rev Immunol (2009) 2.27

Protein folded states are kinetic hubs. Proc Natl Acad Sci U S A (2010) 2.27

Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.27

Predicting small-molecule solvation free energies: an informal blind test for computational chemistry. J Med Chem (2008) 2.27

The Trp cage: folding kinetics and unfolded state topology via molecular dynamics simulations. J Am Chem Soc (2002) 2.26

Everything you wanted to know about Markov State Models but were afraid to ask. Methods (2010) 2.24

Native-like mean structure in the unfolded ensemble of small proteins. J Mol Biol (2002) 2.23

Using massively parallel simulation and Markovian models to study protein folding: examining the dynamics of the villin headpiece. J Chem Phys (2006) 2.22

GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity (2003) 2.18

MSMBuilder2: Modeling Conformational Dynamics at the Picosecond to Millisecond Scale. J Chem Theory Comput (2011) 2.15

Antigen recognition determinants of gammadelta T cell receptors. Science (2005) 2.14

Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol (2005) 2.12

Structure of the measles virus hemagglutinin. Nat Struct Mol Biol (2007) 2.11

OpenMM 4: A Reusable, Extensible, Hardware Independent Library for High Performance Molecular Simulation. J Chem Theory Comput (2012) 2.07

Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition. Neuron (2003) 2.06

A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron (2005) 2.03

Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity (2005) 2.03

How well can simulation predict protein folding kinetics and thermodynamics? Annu Rev Biophys Biomol Struct (2005) 1.98

Simulations of the role of water in the protein-folding mechanism. Proc Natl Acad Sci U S A (2004) 1.95

Atomistic folding simulations of the five-helix bundle protein λ(6−85). J Am Chem Soc (2011) 1.94

Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med (2004) 1.89

Direct calculation of the binding free energies of FKBP ligands. J Chem Phys (2005) 1.88

Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 1.88

T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity (2011) 1.86

Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation (2005) 1.82

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81

Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure (2010) 1.79

To milliseconds and beyond: challenges in the simulation of protein folding. Curr Opin Struct Biol (2012) 1.77

Graded expression of semaphorin-1a cell-autonomously directs dendritic targeting of olfactory projection neurons. Cell (2007) 1.77

Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol (2009) 1.71

Specificity and degeneracy of T cells. Mol Immunol (2004) 1.71

A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70

Error analysis and efficient sampling in Markovian state models for molecular dynamics. J Chem Phys (2005) 1.70

Are Protein Force Fields Getting Better? A Systematic Benchmark on 524 Diverse NMR Measurements. J Chem Theory Comput (2012) 1.68

Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68

Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science (2008) 1.67

IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol (2009) 1.65

Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol (2009) 1.65